Hope for rare neurological disease: extension trial offers continued treatment
Disease control
Terminated
This study provides continued treatment with EryDex to patients with ataxia telangiectasia who completed the previous NEAT trial. The 12-month extension allows researchers to gather more safety data while offering treatment to all eligible participants. The study focuses on monit…
Phase: PHASE3 • Sponsor: Quince Therapeutics S.p.A. • Aim: Disease control
Last updated Mar 02, 2026 15:27 UTC